| Name | Rosmantuzumab |
|---|
| Description | Rosmantuzumab (OMP-131R10) is an anti-R-spondin 3 (RSPO3) humanized monoclonal antibody. Rosmantuzumab can be used for the research of advanced telapsed and refractory solid tumors[1]. |
|---|---|
| Related Catalog | |
| In Vivo | Rosmantuzumab (25 mg/kg;腹腔注射,每周一次,持续 4 周) 显著保护动物免于发生肝纤维化[1]。 Rosmantuzumab (25mg /kg;腹腔注射,每两周一次,持续 6 周) 在博莱霉素诱导的肺纤维化小鼠模型中,显著抑制皮肤厚度、胶原沉积和 α-SMA 阳性细胞数量[1]。 Animal Model: Male C57B1/6J CCl4 liver fibrosis mouse models[1] Dosage: 25 mg/kg Administration: Intraperitoneal injection; 25 mg/kg, once a week for 4 weeks Result: Significantly decreased collagen I and collagen III mRNAs, and inhibits β-catenin cytoplasmic and nuclear translocation. |
| References |
| No Any Chemical & Physical Properties |